Stock listing
NASDAQ:PHAT Phathom Pharmaceuticals, Inc. Stock
Home listing (NASDAQ) of Phathom Pharmaceuticals, Inc.
Follow Phathom Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PHAT
$4.66 USD -0.64 (-12.1%)
Close on Nov 20, 2026
- Day range
- $4.62 – $5.15 USDNov 20, 2026
- Volume
- 1.33M sharesNov 20, 2026
- Market cap
- $378.8M USDAt the close on Nov 20, 2026 · price × 81.29M shares outstanding
- 52-week range
- $4.62 – $18.31 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $10.07M USDMedian day 1.33M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PHAT · Home | $4.66 USD | -0.64 (-12.1%) | 1,330,427 | $5.03 | $5.145 | $4.615 | $5.30 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PHAT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.66 | -0.64 | -12.1% | $5.03 | $5.145 | $4.615 | 1,330,427 | |
| $5.30 | -0.20 | -3.6% | $5.50 | $5.535 | $5.04 | 1,674,833 | |
| $5.50 | -0.38 | -6.5% | $5.925 | $5.954 | $5.47 | 1,060,440 | |
| $5.88 | -0.18 | -3.0% | $6.02 | $6.14 | $5.765 | 1,118,057 | |
| $6.06 | -0.17 | -2.7% | $6.24 | $6.24 | $5.78 | 1,509,711 | |
| $6.23 | -0.05 | -0.8% | $6.21 | $6.376 | $6.10 | 1,087,524 | |
| $6.28 | +0.835 | +15.3% | $5.45 | $6.315 | $5.41 | 1,570,634 | |
| $5.445 | +0.115 | +2.2% | $5.26 | $5.55 | $5.15 | 1,506,615 | |
| $5.33 | +0.08 | +1.5% | $5.455 | $5.49 | $5.18 | 1,938,582 | |
| $5.25 | +0.17 | +3.3% | $5.26 | $5.305 | $5.04 | 1,770,845 | |
| $5.08 | -0.60 | -10.6% | $5.70 | $5.70 | $5.045 | 1,551,248 | |
| $5.68 | -0.06 | -1.0% | $5.95 | $6.13 | $5.66 | 1,504,074 | |
| $5.74 | -0.175 | -3.0% | $5.92 | $6.11 | $5.50 | 2,162,617 | |
| $5.915 | +0.175 | +3.0% | $5.76 | $5.925 | $5.495 | 2,812,512 | |
| $5.74 | -0.48 | -7.7% | $6.32 | $6.32 | $5.59 | 1,618,521 | |
| $6.22 | -0.06 | -1.0% | $7.00 | $7.00 | $5.71 | 3,843,346 | |
| $6.28 | +0.29 | +4.8% | $5.94 | $6.43 | $5.85 | 2,080,738 | |
| $5.99 | +0.05 | +0.8% | $5.945 | $6.18 | $5.815 | 2,103,987 | |
| $5.94 | +0.20 | +3.5% | $5.70 | $6.06 | $5.70 | 2,113,825 | |
| $5.74 | -1.27 | -18.1% | $6.72 | $6.76 | $5.015 | 4,863,900 | |
| $7.01 | -0.02 | -0.3% | $7.04 | $7.217 | $6.965 | 811,700 | |
| $7.03 | -0.28 | -3.8% | $7.31 | $7.48 | $7.01 | 784,200 | |
| $7.31 | +0.30 | +4.3% | $7.04 | $7.40 | $6.96 | 724,300 | |
| $7.01 | +0.09 | +1.3% | $6.88 | $7.05 | $6.78 | 1,017,100 | |
| $6.92 | -0.58 | -7.7% | $7.51 | $7.57 | $6.90 | 1,254,200 | |
| $7.50 | +0.10 | +1.4% | $7.54 | $7.69 | $7.41 | 1,210,200 | |
| $7.40 | +0.40 | +5.7% | $6.97 | $7.72 | $6.918 | 1,721,100 | |
| $7.00 | -0.13 | -1.8% | $7.14 | $7.16 | $6.86 | 1,947,200 | |
| $7.13 | -0.12 | -1.7% | $7.25 | $7.285 | $7.03 | 1,013,700 | |
| $7.25 | +0.12 | +1.7% | $7.13 | $7.30 | $7.015 | 928,300 | |
| $7.13 | +0.32 | +4.7% | $6.79 | $7.18 | $6.68 | 1,334,400 | |
| $6.81 | +0.03 | +0.4% | $6.87 | $7.03 | $6.60 | 1,630,600 | |
| $6.78 | +0.08 | +1.2% | $6.75 | $6.80 | $6.52 | 2,087,800 | |
| $6.70 | -0.22 | -3.2% | $6.95 | $7.00 | $6.645 | 1,104,700 | |
| $6.92 | -0.16 | -2.3% | $7.20 | $7.23 | $6.82 | 1,683,800 | |
| $7.08 | -0.22 | -3.0% | $7.47 | $7.47 | $7.08 | 1,059,700 | |
| $7.30 | -0.06 | -0.8% | $7.40 | $7.50 | $7.19 | 809,100 | |
| $7.36 | +0.01 | +0.1% | $7.34 | $7.45 | $7.185 | 657,200 | |
| $7.35 | +0.05 | +0.7% | $7.30 | $7.41 | $7.15 | 1,690,900 | |
| $7.30 | +0.22 | +3.1% | $7.10 | $7.38 | $7.095 | 1,442,500 | |
| $7.08 | +0.095 | +1.4% | $6.98 | $7.19 | $6.91 | 1,424,500 | |
| $6.985 | -0.775 | -10.0% | $7.825 | $7.825 | $6.98 | 1,042,400 | |
| $7.76 | +0.31 | +4.2% | $7.58 | $7.84 | $7.40 | 1,953,100 | |
| $7.45 | -0.03 | -0.4% | $7.54 | $7.62 | $7.31 | 898,900 | |
| $7.48 | -0.27 | -3.5% | $7.63 | $7.763 | $7.465 | 1,788,500 | |
| $7.75 | +0.06 | +0.8% | $7.81 | $8.00 | $7.59 | 1,499,500 | |
| $7.69 | -0.47 | -5.8% | $8.00 | $8.24 | $7.66 | 2,072,400 | |
| $8.16 | -0.52 | -6.0% | $8.63 | $8.655 | $8.10 | 1,641,900 | |
| $8.68 | +0.32 | +3.8% | $8.45 | $8.83 | $8.35 | 1,315,300 | |
| $8.36 | -0.01 | -0.1% | $8.40 | $8.52 | $8.07 | 1,389,000 | |
| $8.37 | -0.30 | -3.5% | $8.50 | $8.545 | $8.29 | 1,092,300 | |
| $8.67 | -0.76 | -8.1% | $9.32 | $9.32 | $8.64 | 1,109,300 | |
| $9.43 | -0.07 | -0.7% | $9.42 | $9.65 | $9.22 | 1,032,700 | |
| $9.50 | +0.45 | +5.0% | $8.99 | $9.55 | $8.89 | 1,235,700 | |
| $9.05 | -0.21 | -2.3% | $9.30 | $9.311 | $8.984 | 663,100 | |
| $9.26 | -0.13 | -1.4% | $9.45 | $9.73 | $9.05 | 932,600 | |
| $9.39 | -0.18 | -1.9% | $9.55 | $9.675 | $9.15 | 885,000 | |
| $9.57 | +0.39 | +4.2% | $9.17 | $9.695 | $9.04 | 1,211,500 | |
| $9.18 | +0.24 | +2.7% | $8.89 | $9.305 | $8.782 | 894,400 | |
| $8.94 | +0.17 | +1.9% | $8.77 | $8.99 | $8.545 | 1,047,100 | |
| $8.77 | -0.03 | -0.3% | $8.78 | $8.865 | $8.571 | 800,600 | |
| $8.80 | +0.14 | +1.6% | $8.75 | $8.94 | $8.64 | 748,600 | |
| $8.66 | -0.21 | -2.4% | $8.88 | $8.92 | $8.51 | 992,700 | |
| $8.87 | +0.27 | +3.1% | $8.63 | $8.896 | $8.59 | 979,200 | |
| $8.60 | -0.72 | -7.7% | $9.25 | $9.30 | $8.40 | 1,405,600 |
- Ticker
- NASDAQ:PHAT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously
Latest earnings call · Oct 29, 2026
Phathom Pharmaceuticals (NASDAQ:PHAT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Jul 30, 2026
Q2 2026 Earnings Presentation
Earnings · 15 slides
Latest news
Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously
Nov 19, 2026
Closed $4.66 (-12.1%) on Nov 20, 2026
Phathom Pharmaceuticals to Participate in November Investor Conferences
Nov 4, 2026
Closed $5.68 (-1.0%) on Nov 4, 2026
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
Nov 3, 2026
Closed $5.74 (-3.0%) on Nov 3, 2026
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Oct 29, 2026
Closed $6.22 (-1.0%) on Oct 29, 2026
Phathom Pharmaceuticals Provides Update on FDA Litigation
Oct 26, 2026
Closed $5.94 (+3.5%) on Oct 26, 2026
Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026
Oct 19, 2026
Closed $7.01 (+1.3%) on Oct 19, 2026
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
Oct 12, 2026
Closed $7.13 (-1.7%) on Oct 12, 2026
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
Oct 8, 2026
Closed $7.13 (+4.7%) on Oct 8, 2026
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
Sep 29, 2026
Closed $7.36 (+0.1%) on Sep 29, 2026
Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Jul 30, 2026
Closed $9.03 (-22.4%) on Jul 30, 2026
Phathom Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 155 in all · newest Nov 19, 2026 · oldest 2019
- Calls
- 12 calls with a replay · 12 with a transcript · latest Oct 29, 2026
- Decks
- 14 decks · latest Jul 30, 2026
Where Phathom Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PHAT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:PHAT | BOATS | United States | USD |
Valuation
EV/sales 1.3× against a median of 42.0×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $359.8M USD
- P/E
- Loss
- EV/sales
- 1.3×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- 80.7%
- Operating margin
- −9.3%
- Net margin
- −30.2%
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.08
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. · NASDAQ:PHAT | US$378.8M | US$359.8M | n/a | 1.3× | n/a | n/a | −30.2% | n/a | 1.08 |
| Avalo Therapeutics, Inc. · NASDAQ:AVTX | US$390.9M | −US$1.93M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.25 |
| Mezzion Pharma Co., Ltd. · KRX:140410 | US$388.6M | US$358.6M | n/a | 57.3× | n/a | 13.4× | −325.0% | 0.0× | n/a |
| Beijing Luzhu Biotechnology Co., Ltd. Class H · HKEX:2480 | US$388.3M | US$369.0M | n/a | n/a | n/a | 4.3× | n/a | 0.4× | n/a |
| Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H · HKEX:3378 | US$387.5M | US$315.9M | n/a | n/a | n/a | 4.1× | n/a | 0.1× | n/a |
| Qurient Co., Ltd. · KRX:115180 | US$386.1M | US$370.1M | n/a | 70.5× | n/a | 30.2× | −543.0% | 0.8× | n/a |
| Opus Genetics, Inc. · NASDAQ:IRD | US$385.7M | US$332.3M | n/a | 42.0× | n/a | 10.0× | n/a | 0.9× | 1.01 |
| Eupraxia Pharmaceuticals, Inc. · TSX:EPRX | US$384.2M | US$252.6M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | 1.53 |
| Hinova Pharmaceuticals, Inc. Class A · SSE:688302 | US$382.0M | US$286.5M | n/a | 23.0× | n/a | 2.6× | −167.3% | 0.1× | n/a |
| Rezolute, Inc. · NASDAQ:RZLT | US$379.2M | US$289.9M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.28 |
| Qyuns Therapeutics Co., Ltd. Class H · HKEX:2509 | US$370.7M | US$380.6M | 4.5× | 2.5× | 4.2× | 2.9× | 53.3% | 0.8× | n/a |
| Median of the others | US$385.9M | US$324.1M | 4.5× | 42.0× | 4.2× | 4.2× | −246.2% | 0.1× | 1.27 |
Forecasts
8 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 20.05 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.046 · 5 analysts
- Revenue, year to Dec 2026
- 315M · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Asit Parikh | President & Chief Executive Officer, MOMA Therapeutics |
| Steven Basta | President & Chief Executive Officer |
| Sanjeev Narula | Chief Financial and Business Officer |
| Mark Stenhouse | Chief Operating Officer, Prometheus Biosciences |
| Anne Marie Cook | Chief Legal Officer and Corporate Secretary |
| Bill Aprea | Senior Vice President, Chief Compliance Officer and Deputy Chief Legal Officer |
| Jay Buchanan | Senior Vice President, Manufacturing & Supply Chain |
| Jonathan Bentley | Senior Vice President, Head of Sales, Operations, & Training |
| Mark Devlin | Senior Vice President, Market Access |
| Robert Breedlove | Vice President, Finance & Principal Accounting Officer |
| Aditya Kohli | Co-Founder, Phathom |
| Azmi Nabulsi | Co-Founder, Phathom |
| David Socks | Co-Founder, Phathom |
| Eckhard Leifke | Chief Medical Officer |
| Paul Cocja | Chief People Officer |
| Tadataka Yamada | Co-Founder and Late Chairman, Phathom |
Board
| Director | Role |
|---|---|
| Tadataka Yamada | Co-Founder and Late Chairman, Phathom |
| David Socks | Co-Founder, Phathom |
| Heidi Kunz | Director |
| Michael Cola | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q3 2026 Earnings Call | Thu, Oct 29, 2026 · 8:00 AM ET | Replay |
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q2 2026 Earnings Call | Thu, Jul 30, 2026 · 8:00 AM ET | Replay |
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q1 2026 Earnings Call | Thu, Apr 30, 2026 · 8:00 AM ET | Replay |
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 8:00 AM ET | Replay |
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q3 2025 Earnings Call | Thu, Oct 30, 2025 · 8:00 AM ET | Replay |
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 8:00 AM ET | Replay |
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q1 2025 Earnings Call | Thu, May 01, 2025 · 8:00 AM ET | Replay |
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q4 2024 Earnings Call | Thu, Mar 06, 2025 · 8:30 AM ET | Replay |
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 8:30 AM ET | Replay |
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:30 AM ET | Replay |
All 12 calls
| Call | When | Status |
|---|---|---|
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q1 2024 Earnings Call | Mon, May 13, 2024 · 10:00 AM ET | Replay |
| Phathom Pharmaceuticals (NASDAQ:PHAT) Q4 2023 Earnings Call | Thu, Mar 07, 2024 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · Before open | −1.0% |
| Q2 2026 | Jul 30, 2026 · Before open | −22.4% |
| Q1 2026 | May 12, 2026 | +2.8% |
| Q4 2025 | Feb 26, 2026 · Before open | +10.1% |
| Q3 2025 | Oct 30, 2025 · Before open | −1.6% |
| Q2 2025 | Aug 7, 2025 · Before open | +8.3% |
| Q1 2025 | May 7, 2025 · Before open | 0.0% |
| Q4 2024 | Mar 6, 2025 · Before open | −3.0% |
| Q3 2024 | Nov 7, 2024 · Before open | +2.8% |
| Q2 2024 | Aug 8, 2024 · Before open | +8.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −0.1% |
| Q4 2023 | Mar 7, 2024 · Before open | −6.6% |
| Q3 2023 | Nov 9, 2023 · Before open | +0.5% |
| Q2 2023 | Aug 10, 2023 · Before open | +3.7% |
| Q1 2023 | May 10, 2023 · Before open | +3.7% |
| Q4 2022 | Feb 28, 2023 · Before open | −11.8% |
| Q3 2022 | Nov 8, 2022 · After close | −7.5% |
| Q2 2022 | Aug 2, 2022 · Before open | −28.8% |
| Q1 2022 | May 10, 2022 · Before open | −8.1% |
| Q4 2021 | Mar 1, 2022 · After close | +2.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 15 slides | Jul 30, 2026 |
| Investor Presentation (July 2026) | Investor deck | 35 slides | July 2026 |
| Q1 2026 Earnings Presentation | Earnings | 16 slides | Apr 30, 2026 |
| FY2025 Earnings Presentation | Earnings | 15 slides | February 2026 |
| Q3 2025 Earnings Presentation | Earnings | 14 slides | Oct 30, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 14 slides | Aug 7, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 13 slides | May 1, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 22 slides | Mar 6, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 21 slides | Nov 7, 2024 |
| Technical Presentation (October 2024) | Technical | 10 slides | October 2024 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q1 2024 Earnings Presentation | Earnings | 22 slides | May 13, 2024 |
| Technical Presentation (May 2024) | Technical | 23 slides | May 2024 |
| Q4 2023 Earnings Presentation | Earnings | 17 slides | Mar 7, 2024 |
| Fact Sheet (August 2022) | Fact sheet | 2 slides | August 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Update: about US$130M · US$16 a share · Guggenheim Securities +5 Dealers: Guggenheim Securities (co-lead), Cantor (co-lead), Raymond James, Needham & Company, H.C. Wainwright & Co., Craig-Hallum Use of proceeds: General corporate purposes, including working capital and commercialization and research and development expenses | Jan 8, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$19.00 a share on Oct 24, 2019.
- Price
- US$19.00 a share
- Shares offered
- 9,563,157 shares of common stock
- Offering size
- US$181.7 million
- Underwriters' option
- Up to 1,434,473 more shares
- Underwriters
- Goldman Sachs & Co. LLC, Jefferies, Evercore ISI, Needham & Company · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 26, 2019 |
| Filed publicly | Sep 30, 2019 |
| Amended once | Oct 15, 2019 |
| Shares registered with an exchange | Oct 16, 2019 |
| Declared effective by the SEC | Oct 24, 2019 |
| Final prospectus, with the price | Oct 28, 2019 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 28, 2019 |
| EFFECT · Notice that a registration is effective | Oct 24, 2019 |
| S-1MEF · Registration of more shares for the same offering | Oct 24, 2019 |
| CERT · Exchange's certificate of listing | Oct 23, 2019 |
| CORRESP · Letter to the SEC | Oct 22, 2019 |
| CORRESP · Letter to the SEC | Oct 22, 2019 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 16, 2019 |
| S-1/A · Registration statement, amended | Oct 15, 2019 |
| CORRESP · Letter to the SEC | Sep 30, 2019 |
| S-1 · Registration statement | Sep 30, 2019 |
All 16 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | Sep 18, 2019 |
| UPLOAD · Letter from the SEC | Sep 16, 2019 |
| DRSLTR · Letter to the SEC with a draft | Aug 30, 2019 |
| DRS/A · Draft registration statement, amended | Aug 30, 2019 |
| UPLOAD · Letter from the SEC | Aug 23, 2019 |
| DRS · Draft registration statement | Jul 26, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 28, 2019
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 175.1M | 55.3M | 682.0K | 0 | ||||
| Cost of revenue | 22.6M | 7.97M | 167.0K | 0 | ||||
| Gross profit | 152.5M | 47.3M | 515.0K | 0 | ||||
| Research and development | 32.8M | 34.1M | 49.9M | 71.4M | 72.3M | 98.1M | 20.4M | 20.0K |
| Selling, general and administrative | 279.7M | 290.7M | 117.9M | 101.0M | ||||
| Operating income | -160.0M | -277.5M | -167.3M | -172.4M | -135.1M | -125.7M | -106.2M | -1.23M |
| Depreciation and amortization | 633.0K | 795.0K | 575.0K | 620.0K | 521.0K | 323.0K | 8.00K | 0 |
| EBITDA | -159.4M | -276.7M | -166.7M | -171.8M | -134.6M | -125.3M | -106.2M | -1.23M |
| Interest expense | 68.1M | 72.0M | 42.0M | 27.3M | 6.79M | 4.58M | 4.18M | 13.0K |
| Income before tax | -221.2M | -334.3M | ||||||
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -221.2M | -334.3M | -201.6M | -197.7M | -143.9M | -129.1M | -255.1M | -1.29M |
| Earnings per share, basic | -3.03 | -5.29 | -3.93 | -5.05 | -3.89 | -3.88 | -22.45 | -0.21 |
| Earnings per share, diluted | -3.03 | -5.29 | -3.93 | -5.05 | -3.89 | -3.88 | -22.45 | -0.21 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 130.0M | 297.3M | 381.4M | 155.4M | 183.3M | 287.5M | 243.8M | 879.0K |
| Receivables | 78.1M | 38.8M | 1.64M | 0 | ||||
| Inventory | 5.52M | 3.21M | 1.21M | 0 | ||||
| Current assets | 229.0M | 360.1M | 397.4M | 160.5M | 186.5M | 291.4M | 255.6M | 902.0K |
| Property, plant and equipment | 1.06M | 1.48M | 2.15M | 1.21M | 650.0K | 986.0K | 463.0K | |
| Total assets | 259.1M | 378.3M | 413.8M | 164.8M | 189.4M | 295.1M | 257.2M | 902.0K |
| Accounts payable | 4.98M | 10.5M | 12.6M | 10.00M | 5.15M | 16.8M | 699.0K | 55.0K |
| Current liabilities | 132.0M | 85.7M | 38.8M | 26.2M | 18.9M | 55.5M | 3.75M | 2.19M |
| Long-term debt | 209.1M | 201.4M | 137.8M | 95.3M | 89.7M | 39.6M | 22.8M | |
| Total debt | 209.1M | 201.4M | 137.8M | 95.3M | 89.7M | 47.0M | 22.8M | |
| Total liabilities | 697.3M | 631.9M | 486.6M | 239.6M | 117.3M | 100.8M | 29.2M | 2.19M |
| Shareholders' equity | -438.2M | -253.6M | -72.8M | -74.8M | 72.2M | 194.3M | 228.0M | -1.29M |
| Shares outstanding | 71.4M | 68.5M | 58.0M | 41.5M | 30.5M | 28.5M | 24.7M | 6.76M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -166.8M | -266.8M | -137.6M | -146.5M | -148.5M | -69.7M | -36.5M | -1.02M |
| Capital spending | -229.0K | -135.0K | -1.63M | -1.04M | -328.0K | -1.04M | -132.0K | |
| Free cash flow | -167.0M | -266.9M | -139.2M | -147.6M | -148.8M | -70.7M | -36.6M | |
| Cash from investing | -229.0K | -135.0K | -1.63M | -1.04M | -328.0K | -1.04M | -25.3M | |
| Cash from financing | -288.0K | 182.8M | 367.6M | 120.0M | 44.7M | 114.5M | 304.6M | 1.90M |
| Change in cash | -167.3M | -84.1M | 228.4M | -27.5M | -104.1M | 43.7M | 242.9M | 879.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 18, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 2, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2026 | Results | SEC |
| 8-K · Current report | Oct 26, 2026 | Current report | SEC |
| 8-K · Current report | Oct 23, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 20, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Current report | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 8-K · Current report | May 21, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Apr 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 7, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 7, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 7, 2026 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jan 8, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jan 7, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 7, 2026 | Results | SEC |
| S-3ASR · Registration statement | Jan 7, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 3, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2025 | Results | SEC |
| 8-K · Current report | Oct 27, 2025 | Current report | SEC |
| 4/A · Change in ownership, amended | Oct 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 6, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 28, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 25, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 20, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2025 | Current report | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 9, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 6, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 15, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 6, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 23, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 16, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 16, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 3, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Apr 3, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 1, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Mar 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 6, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 6, 2025 | Results | SEC |
| 10-K · Annual report | Mar 6, 2025 | Annual report | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2024 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 5, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 21, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 22, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 19, 2024 | Current report | SEC |
| 424B5 · Prospectus | Aug 19, 2024 | Offer document | SEC |
| FWP · Free writing prospectus | Aug 19, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 8-K · Current report | Jul 18, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2024 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jun 25, 2024 | Other filings | SEC |
| 10-K/A · Annual report, amended | Jun 14, 2024 | Annual report | SEC |
| 10-Q/A · Quarterly report, amended | Jun 14, 2024 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | Jun 14, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Jun 6, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Jun 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2024 | Insider trade | SEC |
| 8-K · Current report | May 24, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 12, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 12, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 12, 2024 | Annual report | SEC |
| 4 · Change in ownership | Apr 10, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 10, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 1, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 26, 2024 | Insider trade | SEC |
| 10-K · Annual report | Mar 7, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 7, 2024 | Results | SEC |
| 8-K · Current report | Feb 13, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 26, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 25, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 25, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2023 | Current report | SEC |
| 8-K · Current report | Dec 14, 2023 | Material contract | SEC |
| 8-K · Current report | Dec 6, 2023 | Current report | SEC |
| 8-K · Current report | Nov 28, 2023 | Current report | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Nov 20, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 15, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 15, 2023 | Other filings | SEC |
| S-3 · Registration statement | Nov 9, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 4 · Change in ownership | Nov 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 1, 2023 | Current report | SEC |
| 8-K · Current report | Oct 30, 2023 | Current report | SEC |
| 8-K · Current report | Sep 26, 2023 | Current report | SEC |
| 8-K · Current report | Aug 21, 2023 | Current report | SEC |
This page holds 200 of 497 filings. Open Filings
Cap table
Built by 6ix from Phathom Pharmaceuticals, Inc.’s releases · as of Oct 27, 2026
- Common shares
- 81,291,520
- Fully diluted
- 81,291,520
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 81,291,520 | Oct 27, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 27, 2026 | 81,291,520 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James N Topper Other companies: Attovia Therapeutics, Inc. (Director · Since at least Aug 4, 2026); NewAmsterdam Pharma Company N.V. (Director · Since at least Dec 29, 2023); Frazier Lifesciences Acquisition Corp (Chief Executive Officer, Director · Dec 8, 2020 – Dec 11, 2020 · Past); Entasis Therapeutics Holdings Inc (Director · Sep 25, 2018 – Jan 18, 2019 · Past); Aptinyx Inc (Director · Jun 20, 2018 – Mar 31, 2020 · Past); Allena Pharmaceuticals Inc (Director · Nov 1, 2017 – Nov 17, 2020 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – May 18, 2024 · Past); AnaptysBio, Inc. (Director · Jan 25, 2017 – Jan 6, 2023 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Feb 14, 2017 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – Jun 5, 2013 · Past); Amicus Therapeutics Inc (Director · Jun 15, 2010 – Jun 12, 2014 · Past) | Director · Since at least Oct 24, 2019 |
| Theodore R Schroeder Other companies: Cidara Therapeutics Inc (Director · Since at least Apr 14, 2015); Nabriva Therapeutics AG (Director · Jul 24, 2018 – Jan 29, 2023 · Past); Collegium Pharmaceutical, Inc. (Director · Jan 22, 2016 – May 20, 2020 · Past); Otonomy Inc (Director · Aug 28, 2015 – Jun 21, 2022 · Past); Hyperion Therapeutics Inc (Director · Aug 11, 2014 – May 7, 2015 · Past); Trius Therapeutics Inc (Director · Aug 2, 2010 – Sep 11, 2013 · Past); Cadence Pharmaceuticals Inc (President, CEO, Director · Oct 24, 2006 – Mar 19, 2014 · Past) | Director · Since at least Apr 16, 2025 |
| Frank Karbe Other companies: Cidara Therapeutics Inc (Chief Financial Officer · Since at least Feb 24, 2025); Better Therapeutics, Inc. (Chief Executive Officer, Director · Jul 5, 2022 – Dec 18, 2023 · Past); Aduro Biotech Inc (Director · Apr 18, 2019 – May 5, 2020 · Past); Myovant Sciences Ltd (Principal Fin'l & Accounting · Oct 26, 2016 – Jul 7, 2021 · Past); Arbutus Biopharma Corporation (Director · Dec 31, 2014 – Jun 21, 2017 · Past); Exelixis, Inc. (EVP and CFO · Dec 8, 2006 – Feb 15, 2014 · Past) | Director · Since at least Apr 25, 2022 |
| Michael Cola Other companies: Sage Therapeutics Inc (Director · Since at least Sep 11, 2014); Avalo Therapeutics, Inc. (Chief Executive Officer, Director · Feb 3, 2020 – Oct 1, 2021 · Past); Aevi Genomic Medicine LLC (Chief Executive Officer, Director · Sep 13, 2013 – Jun 9, 2020 · Past); Vanda Pharmaceuticals Inc. (Director · Jun 14, 2012 – Jun 13, 2019 · Past); NuPathe Inc. (Director · Sep 30, 2011 – Feb 21, 2014 · Past) | Director · Since at least Oct 24, 2019 |
| Molly Henderson Other companies: UroGen Pharma Ltd. (Chief Financial Officer · Oct 1, 2020 – Jan 31, 2022 · Past); Advaxis Inc (Executive Vice President & CFO · Jun 6, 2018 – May 4, 2020 · Past); Iovance Biotherapeutics, Inc. (CFO · Jun 8, 2015 – Jun 1, 2016 · Past); VirtualScopics Inc (Chief Business/Financial Off. · May 30, 2006 – Jan 29, 2013 · Past) | CFO and CBO · Apr 5, 2022 – Apr 7, 2025 · Past |
| Steven L Basta Other companies: VYNE Therapeutics Inc. (Director · Since at least Jul 19, 2021); Viveve Medical, Inc. (Director · Sep 13, 2018 – Jan 3, 2023 · Past); Carbylan Therapeutics Inc (Director · Apr 8, 2015 – Aug 3, 2015 · Past); Bioform Medical Inc (Chief Executive Officer, Director · Nov 5, 2007 – Feb 16, 2010 · Past) | President and CEO, Director · Since at least Apr 1, 2025 |
| Anne Marie Cook Other companies: Sage Therapeutics Inc (SVP, GC & Secretary · Sep 16, 2015 – Aug 5, 2024 · Past); Aegerion Pharmaceuticals Inc (SVP, General Counsel · Dec 5, 2011 – Aug 4, 2015 · Past) | Chief Legal Officer and Corporate Secretary · Since at least Jun 23, 2025 |
| David Socks Other companies: Hillevax Inc (CFO & Chief Business Officer · Apr 28, 2022 – Apr 28, 2022 · Past); Cadence Pharmaceuticals Inc (SVP · Oct 24, 2006 – Jun 14, 2010 · Past) | Co-Founder, Phathom · Since at least Oct 24, 2019 |
| Heidi Fields Other companies: Agilent Technologies, Inc. (Director · Nov 23, 2022 – Mar 14, 2025 · Past); Icosavax Inc (Director · Jun 10, 2022 – Jun 6, 2023 · Past) | Director · Since at least May 25, 2022 |
| Mark Stenhouse Other companies: Prometheus Biosciences Inc (Chief Operating Officer · Mar 11, 2021 – Jun 16, 2023 · Past); EXACT Sciences Corporation (President, Cologuard · Apr 2, 2018 – Apr 2, 2020 · Past) | Chief Operating Officer, Prometheus Biosciences · Since at least Mar 17, 2020 |
All 30 people
| Person | Seat |
|---|---|
| Sanjeev Narula Other companies: Intra-Cellular Therapies Inc (Executive Vice President & CFO · Aug 12, 2024 – Apr 2, 2025 · Past); Viatris Inc. (Chief Financial Officer · Aug 6, 2020 – Mar 2, 2023 · Past) | Chief Financial and Business Officer · Since at least Oct 6, 2025 |
| Todd P Branning Other companies: NeuBase Therapeutics Inc (Chief Financial Officer · Jan 10, 2022 – Mar 16, 2023 · Past); Amneal Pharmaceuticals, Inc. (SVP and CFO · Jan 21, 2019 – Feb 27, 2020 · Past) | Chief Financial Officer · Jul 13, 2020 – Jan 28, 2021 · Past |
| Aditya Kohli Other companies: Hillevax Inc (Director · Since at least Apr 28, 2022) | Co-Founder, Phathom · Since at least Oct 24, 2019 |
| Terrie Curran Other companies: Arcutis Biotherapeutics, Inc. (Director · Since at least Jun 14, 2024) | President and Chief Executive, Director · Nov 1, 2023 – Feb 27, 2025 · Past |
| Anthony J Guzzo | VP, Chief Accounting Officer · Jun 4, 2021 – Jan 19, 2022 · Past |
| Asit Parikh | President & Chief Executive Officer, MOMA Therapeutics · Since at least Dec 2, 2019 |
| Azmi Nabulsi | Co-Founder, Phathom · Since at least Oct 24, 2019 |
| Bill Aprea | Senior Vice President, Chief Compliance Officer and Deputy Chief Legal Officer · Since at least Nov 4, 2026 |
| Christopher W Slavinsky | Director · Oct 24, 2019 – Oct 24, 2019 · Past |
| Eckhard Leifke | Chief Medical Officer · Since at least Apr 28, 2025 |
| Frank Karbe | Cidara Therapeutics · May 21, 2026 – Oct 8, 2026 · Past |
| Heidi Kunz | Director · Since at least Nov 4, 2026 |
| Jay Buchanan | Senior Vice President, Manufacturing & Supply Chain · Since at least Nov 4, 2026 |
| Jonathan Bentley | Senior Vice President, Head of Sales, Operations, & Training · Since at least May 1, 2025 |
| Mark Devlin | Senior Vice President, Market Access · Since at least Nov 4, 2026 |
| Paul Cocja | Chief People Officer · Since at least Nov 4, 2026 |
| Robert Breedlove | Vice President, Finance & Principal Accounting Officer · Since at least May 1, 2025 |
| Steven Basta | President & Chief Executive Officer · Since at least Jul 30, 2026 |
| Tadataka Yamada | Co-Founder and Late Chairman, Phathom · Since at least Apr 28, 2025 |
| Ted Schroeder | Since at least May 1, 2025 |
Log in to ask 6ix AI your own questions about Phathom Pharmaceuticals, Inc.